Jorge Aguilar
Payments from drug & device makers
Across 530 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$851
- Corcept Therapeutics$700
- Bayer$634
- Mannkind Corporation$629
- plus $5K from 31 others
What the payments were for
- Food & beverage$10,513100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 67 | $1,251 |
| Novo Nordisk | 71 | $1,216 |
| Sanofi-aventis U.S. LLC | 41 | $851 |
| Corcept Therapeutics | 34 | $700 |
| Bayer | 30 | $634 |
| Mannkind Corporation | 30 | $629 |
| Tandem Diabetes Care, Inc. | 20 | $611 |
| Boehringer Ingelheim | 27 | $607 |
| Insulet Corporation | 25 | $442 |
| Amneal Pharmaceuticals LLC | 28 | $437 |
| Xeris Pharmaceuticals, Inc. | 21 | $421 |
| AbbVie | 18 | $310 |
| Amgen | 19 | $254 |
| BETA Bionics, Inc. | 8 | $185 |
| Dexcom, Inc. | 9 | $183 |
| Radius Health, Inc. | 8 | $172 |
| Lifescan, Inc. | 9 | $168 |
| Novartis | 7 | $147 |
| Kyowa Kirin, Inc. | 5 | $145 |
| Embecta Corp. | 7 | $128 |
| BD | 6 | $125 |
| Medtronic | 3 | $119 |
| Abbott | 5 | $116 |
| IBSA Pharma Inc. | 4 | $88 |
| AstraZeneca | 5 | $80 |
| Cequr Corporation | 1 | $77 |
| Ascendis Pharma Endocrinology Inc | 3 | $63 |
| Amarin Pharma, Inc. | 4 | $63 |
| Intuity Medical Inc | 3 | $58 |
| Merck | 3 | $46 |
| Madrigal Pharmaceuticals | 2 | $46 |
| Sequel Med Tech, LLC | 2 | $43 |
| Hologic Sales And Service, LLC | 1 | $32 |
| Evoke Pharma, Inc. | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Nevro Corp. | 1 | $21 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,525 in reported general payments places this provider in the 95th percentile of 2,031 medical providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 484 | $549,281 |
| OzempicSemaglutide | 359 | $384,352 |
| JardianceEmpagliflozin | 369 | $303,615 |
| FarxigaDapagliflozin Propanediol | 207 | $182,131 |
| RybelsusSemaglutide | 153 | $170,008 |
| Tresiba Flextouch U-100Insulin Degludec | 197 | $103,959 |
| Tresiba Flextouch U-200Insulin Degludec | 99 | $87,704 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 134 | $75,601 |
| TrulicityDulaglutide | 63 | $71,415 |
| TradjentaLinagliptin | 96 | $67,917 |
| Humalog Kwikpen U-100Insulin Lispro | 220 | $63,438 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 78 | $58,534 |
| SynjardyEmpagliflozin/Metformin Hcl | 66 | $45,996 |
| Novolog FlexpenInsulin Aspart | 136 | $39,321 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 47 | $37,888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,251 | $623,783559 claims |
| Novo NordiskOzempic, Rybelsus | $1,216 | $554,360512 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy, Trijardy Xr | $607 | $521,903667 claims |
| AstraZenecaFarxiga | $80 | $182,131207 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $851 | $37,88847 claims |
| AmgenProlia | $254 | $35,19520 claims |
| MerckJanuvia, Janumet Xr | $46 | $21,80528 claims |
| AbbVieSynthroid | $310 | $10,847119 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $437 | $5,376577 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,031 medical providers in Florida.
Other medical in Miami
- Ilanit SamuelsMiami$211K
- Anay CastroMiami$18K
- Polina DasguptaMiami$17K
- Maria SorensenMiami$15K
- Carrie HerzogMiami$14K
- Jesus RodriguezMiami$14K
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.